Estrogens and prostate cancer

Dobbs, Ryan W.; Malhotra, Neha; Greenwald, David; Wang, Alice Y.; Prins, Gail S.; Abern, Michael R.

doi:10.1038/s41391-018-0081-6

Cited by 63 publications

(57 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In conclusion, our results showed that exposure to chlordecone, an environmental EDCs with estrogenic properties, at the time of PCa diagnosis is significantly associated with a risk of BCR after prostatectomy. Increasing evidence suggests that estrogens are critical players in human PCa . Our findings add support to the hypothesis that human exposure to environmental estrogens may influence PCa progression.…”

Section: Discussionsupporting

confidence: 84%

See 1 more Smart Citation

Endocrine disrupting‐chemicals and biochemical recurrence of prostate cancer after prostatectomy: A cohort study in Guadeloupe (French West Indies)

Brureau

Emeville

Hélissey

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

Previous studies have suggested that exposure to environmental chemicals with hormonal properties, also called endocrine disrupting chemicals, may be involved in the occurrence of prostate cancer (PCa). Such exposure may also influence the treatment outcome as it is still present at the time of diagnosis, the beginning of therapy, and beyond. We followed 326 men in Guadeloupe (French West Indies) who underwent radical prostatectomy as primary treatment of localized PCa. We analyzed the relationship between exposure to the estrogenic chlordecone, the antiandrogenic dichlorodiphenyldichloroethylene (DDE, the main metabolite of the insecticide DDT), and the nondioxin‐like polychlorinated biphenyl congener 153 (PCB‐153) with mixed estrogenic/antiestrogenic properties and the risk of biochemical recurrence (BCR) after surgery. After a median follow‐up of 6.1 years after surgery, we found a significant increase in the risk of BCR, with increasing plasma chlordecone concentration (adjusted hazard ratio = 2.51; 95% confidence interval: 1.39–4.56 for the highest vs. lowest quartile of exposure; p trend = 0.002). We found no associations for DDE or PCB‐135. These results shown that exposure to environmental estrogens may negatively influence the outcome of PCa treatment.

show abstract

Section: Discussionsupporting

confidence: 84%

“…Increasing evidence suggests that estrogens are critical players in human PCa. 49,50 Our findings add support to the hypothesis that human exposure to environmental estrogens may influence PCa progression.…”

Section: Discussionsupporting

confidence: 79%

Endocrine disrupting‐chemicals and biochemical recurrence of prostate cancer after prostatectomy: A cohort study in Guadeloupe (French West Indies)

Brureau

Emeville

Hélissey

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…The function of ESR1 in NEPC has not yet been investigated, while its role on prostate tissue is ascertained. For this reason, there is an increasing interest in the use of SERMs (selective estrogen receptor modulators) as a potential singular or adjunctive agents for the treatment of PCa [37], with many ongoing clinical trials. Raloxifene, a mixed estrogen agonist/antagonist, has demonstrated some favorable results, particularly in androgen-independent CRPC [38][39][40].…”

Section: Discussionmentioning

confidence: 99%

Gene Expression Signature Predictive of Neuroendocrine Transformation in Prostate Adenocarcinoma

Ostano

Mello-Grand

Sesia

et al. 2020

IJMS

View full text Add to dashboard Cite

Neuroendocrine prostate cancer (NEPC) can arise de novo, but much more commonly occurs as a consequence of a selective pressure from androgen deprivation therapy or androgen receptor antagonists used for prostate cancer (PCa) treatment. The process is known as neuroendocrine transdifferentiation. There is little molecular characterization of NEPCs and consequently there is no standard treatment for this kind of tumors, characterized by highly metastases rates and poor survival. For this purpose, we profiled 54 PCa samples with more than 10-years follow-up for gene and miRNA expression. We divided samples into two groups (NE-like vs. AdenoPCa), according to their clinical and molecular features. NE-like tumors were characterized by a neuroendocrine fingerprint made of known neuroendocrine markers and novel molecules, including long non-coding RNAs and components of the estrogen receptor signaling. A gene expression signature able to predict NEPC was built and tested on independently published datasets. This study identified molecular features (protein-coding, long non-coding, and microRNAs), at the time of surgery, that may anticipate the NE transformation process of prostate adenocarcinoma. Our results may contribute to improving the diagnosis and treatment of this subgroup of tumors for which traditional therapy regimens do not show beneficial effects.

show abstract

“…Also, PCa ranks the fth leading cause of cancer death worldwide (2).With the development of economy and society, China is experiencing a transition stage from a developing country into a developed country, named as "westernized lifestyle-related cancer", so we can effortlessly draw the conclusion that there is an ascendant tendency in the incidence rates of PCa (3). Many conventional high-risk factors have been concerned with the period of tumorigenesis, invasion and metastasis of PCa, including genetic, environmental and life-style factors (4,5).…”

Section: Introductionmentioning

confidence: 99%

A novel analysis of the differentiated expression of long noncoding RNAs profiles in human prostate cancer

Ge¹,

Mi²,

Zhao³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Long noncoding RNAs (lncRNAs) have been proved to be an important regulator in gene expression. In almost all kinds of cancers, lncRNAs participated in the process of pathogenesis, invasion, and metastasis. Meanwhile, compared with the large amounts of patients, there is rare knowledge about the role of lncRNAs in prostate cancer (PCa).Material/Method: In this study, lncRNA expression profiles of prostate cancer were detected by Agilent microarray chip, 5 pairs of case and control specimens were involved in. Differentially expressed lncRNAs were screened out by volcano plot for constructing lncRNA-miRNA-mRNA central network. Then, the top ten up-regulated and down-regulated lncRNAs were validated by qRT-PCR in another 5 tumor specimens and 7 para-cancerous/benign contrasts. Furthermore, we searched for the survival curve of the top 10 upregulated and downregulated lncRNAs.Results: A total of 817 differentially expressed lncRNAs were filtered out by the criteria of fold change (FC) and t-test p < 0.05. Among them, 422 were upregulated, whereas 395 were downregulated in PCa tissues. Gene ontology and KEGG pathway analyses showed that many lncRNAs were implicated in carcinogenesis. lnc-MYL2-4:1 (FC = 0.00141, p = 0.01909) and NR_125857 (FC = 59.27658, p = 0.00128) had the highest magnitude of change. The subsequent qPCR confirmed the expression of NR_125857 was in accordance with the clinical samples. High expression of PCA3, PCAT14 and AP001610.9 led to high hazard ratio while low expression of RP11-279F6.2 led to high hazard ratio.Conclusions: Our study detected a relatively novel complicated map of lncRNAs in PCa, which may have the potential to investigate for diagnosis, treatment and follow-up in PCa. Our study revealed the expression of NR_125857 in human PCa tissues was most up-regulated. Further studies are needed to investigate to figure out the mechanisms in PCa.

show abstract

Estrogens and prostate cancer

Abstract: Estrogens represent a under-recognized contributor in CaP development and progression. Further research in this topic may provide opportunities for identification of environmental influencers as well as providing novel therapeutic targets in the treatment of CaP.

Cited by 63 publications

References 88 publications

Endocrine disrupting‐chemicals and biochemical recurrence of prostate cancer after prostatectomy: A cohort study in Guadeloupe (French West Indies)

Endocrine disrupting‐chemicals and biochemical recurrence of prostate cancer after prostatectomy: A cohort study in Guadeloupe (French West Indies)

Gene Expression Signature Predictive of Neuroendocrine Transformation in Prostate Adenocarcinoma

A novel analysis of the differentiated expression of long noncoding RNAs profiles in human prostate cancer

Contact Info

Product

Resources

About